Imfinzi

News

Imfinzi becomes first NHS drug for aggressive lung cancer

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

News

AZ claims EU okay for Imfinzi in bladder cancer

AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.

News

AZ plots wider Imfinzi use in bladder cancer after trial win

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder cancer.

News

AZ grabs pair of EU approvals for top cancer drugs

AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.

News

FDA clears AZ's Imfinzi for aggressive lung cancer

AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).

News

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.

Imfinzi becomes first NHS drug for aggressive lung cancer

AZ claims EU okay for Imfinzi in bladder cancer

AZ plots wider Imfinzi use in bladder cancer after trial win

AZ grabs pair of EU approvals for top cancer drugs

FDA clears AZ's Imfinzi for aggressive lung cancer

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Imfinzi

Editor's Picks